Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative”

Group 1 - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company focused on using automation, data science, and AI to accelerate drug discovery for genetic, infectious, and cancer-related diseases [2] - The stock has experienced significant volatility, described as "horrendous" by market commentators, and is currently categorized as speculative [1][2] - The company has undergone an equity offering which negatively impacted its stock price, leading to its current status as a "meme stock" with unpredictable trading patterns [2] Group 2 - Despite the potential of RXRX, there are other AI stocks in the market that are perceived to offer greater upside potential and lower downside risk [2] - The stock has garnered attention from retail investors, leading to increased buying activity, particularly noted in the mornings [2]